Aarti Drugs Limited (Aarti Drugs) (NSE: AARTIDRUGS; BSE:524348), a Mumbai based diversified and fully integrated pharmaceutical company, with interests in Active Pharmaceutical Ingredients (API), Formulation, Specialty Chemicals and Intermediates has won Pharmexcil Outstanding Exports Award 2021-2022.
Company has received Export Performance Award - API & Intermediaries Gold Star for the year 2021-22 on July 5th, 2023, in recognition of commendable contribution to the pharmaceutical export of India.
A ministry set up by the Government of India as a gateway to global pharma trade, Pharmexcil presents awards each year to salute those companies that demonstrate excellence in developing proprietary products granted patents throughout the world. The awards were presented during the "iPHEX 9 th edition of Indian Pharmaceutical Exhibition" organized by the Pharmaceuticals Export Promotion Council (Pharmexcil) and sponsored by Department of Commerce & Industry, Government of India where all the major India Pharmaceutical companies had participated. Here the evaluation for the award is based on the value of exports by a company to all the regions of the world and the coverage in terms of the number of countries to which export is made.
Commenting on the same, Mr. Adhish Patil, CFO & COO, Aarti Drugs Limited said, "This recognition by Pharmexcil once again for our profound dedication to the innovation and science behind the products we develop and market worldwide is gratifying and inspiring. We shall, as always, strive to continue contributing our best in every way possible to achieve bigger goals in future."
Shares of Aarti Drugs Limited was last trading in BSE at Rs. 470.30 as compared to the previous close of Rs. 466.95. The total number of shares traded during the day was 8158 in over 744 trades.
The stock hit an intraday high of Rs. 474.15 and intraday low of 463.00. The net turnover during the day was Rs. 3838672.00.